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ABSTRACTS
Gregory L. Moneta, MD, Abstracts Section EditorDescending Thoracic Aortic Aneurysm Repair: 12-year Experience
Using Distal Aortic Perfusion and Cerebrospinal Fluid Drainage
Estrera AL, Miller CC III, Chen EP, et al. Ann Thorac Surg 2005;80:
1290-6.
Conclusion: There is a low incidence of neurologic morbidity and a
relatively low mortality rate following descending thoracic aortic aneurysm
repair when distal aortic perfusion and cerebrospinal fluid drainage are
routinely utilized.
Summary: The authors sought to document their rate of neurologic
deficit andmortality following thoracic aneurysm repair with routine utilization
of distal aortic perfusion and cerebrospinal fluid drainage. There were 355
descending thoracic aortic aneurysms repaired at the author’s institution be-
tween February 1991 and September 2004. Twenty nine patients were ex-
cluded from analysis because of involvement of the aortic arch and 26 patients
with rupturewere also excluded. Therewere therefore 300 patients analyzed for
outcomes. Of these, 198 (66%) were men and 102 (35%) were women. Mean
age was 67 years. A combination of distal aortic perfusion and cerebrospinal
fluid drainage was utilized in 238 patients. There were 62 patients who under-
went simple cross-clamp without utilization of distal aortic perfusion or CSF
drainage.
There was a 2.3% incidence of neurologic deficit in this series (7 of 300
patients). The rate of neurologic deficits in the patients treated with cere-
brospinal fluid drainage and distal aortic perfusion was 1.3% (3 of 238
patients). The rate of neurologic deficit in patients not treated with cerebro-
spinal fluid drainage and distal aortic perfusion was 6.5% (4 of 62 patients; P
0.02). Neurologic deficits in both groups were only seen when the aneurysm
involved the entire descending thoracic aorta. Predictors of neurologic
deficit included use of cerebrospinal fluid drainage and distal aortic perfusion
(odds ratio [OR] 0.19; P  0.02), previous repaired abdominal aortic
aneurysm (OR, 7.0; P  0.005) and aneurysm that involved the entire
descending thoracic aorta (OR 13.73; P  0.02) and a history of cerebro-
vascular disease (OR 4.7; P 0.03). Thirty-day operative mortality was 8%.
Predictors of 30 daymortality were preoperative renal dysfunction (OR, 4.6;
P  0.01) and female sex (OR, 2.9; P  0.03).
Comment:This paper fromDr. Safi’s group inHouston indicates what
is possible to achieve with open thoracic aneurysm repair. I doubt this
volume of patients and this level of expertise is present in many institutions.
Because of this, papers such as this cannot really be used to justify or not
justify endovascular techniques of thoracic aneurysm repair. However, with
data such as this it would seem silly not to provide, when possible, CSF
drainage and distal aortic perfusion in patients undergoing open descending
thoracic aortic aneurysm repair.
MRI vs Helical CT for Endoleak Detection After Endovascular Aneu-
rysm Repair
Pitton NB, Schweitzer H, Herber S, et al. Am J Radiol 2005;185:1275-81.
Conclusion:MRI is far superior to biphasic CT scans for detection of
endoleaks following endovascular aneurysm repair.
Summary: There were 99 patients treated with Nitinol based stent
grafts between 1998-2003 at the author’s institution. Of these 47 were
excluded from analysis because they had follow up at another institution or
did not agree to undergo both CT and MRI imaging in follow up or had
claustrophobia or contrast allergy or poor renal function. Fifty-two patients
therefore had follow up data sets that included MRI and contrast enhanced
biphasic CT scans performed within 48 hours after stent graft placement and
at 3, 6, and 12 months and yearly thereafter. Endoleaks were categorized as
the percent of maximum cross sectional aneurysm area (3%, 3%  10%,
10%  30%, or 30%).
There were 252 data sets available for analysis and 141 showed evi-
dence of endoleak. Incidence of Types 1, 2, 3 and complex endoleak were
3.2%, 40.1%, 8.7%, and 4.0%, respectively. Sensitivities for endoleak detec-
tion forMRI, biphasic CT, uniphasic arterial CT, and uniphasic late CTwere
92.9%, 44.0%, 34.8%, and 38.3%, respectively. Corresponding negative
predictive values were 91.7%, 58.4%, 54.7%, and 56.1%. Overall accuracies
for MRI, biphasic CT, uniphasic arterial CT, and uniphasic late CT, were
95.2%, 58.3%, 55.6%, and 57.1%, respectively.
Comment: The data clearly implied that endoleak rates after endovas-
cular aneurysm repair are dependent upon the imaging modality utilized to
detect the endoleak. MRI appears to detect more endoleaks than CT. It is
interesting to speculate whether unexplained endotension after endovascu-
lar aneurysm repair essentially reflects undetected endoleak. Perhaps unex-
plained endotension after endovascular aneurysm repair would be explainedfar more often if MRI rather than CT was used routinely in the evaluation of
endoleaks following endovascular aortic aneurysm repair.
Trends in Serum Lipids and Lipoproteins of Adults 1960-2002
Carroll MD, Lacher DA, Sorlie PD, et al. JAMA 2005;294:1773-81.
Conclusion: Total cholesterol and LDL cholesterol levels show
continued decline from 1960-2002 with attainment of the target value of
no more than 17% of US adult population of having a total cholesterol
level 240 mg/dl.
Summary: Both total and low density lipoprotein (LDL) cholesterol
levels have been followed by the National Health and Nutrition Examina-
tion Surveys (NHANES) from 1960-2002. Overall both total and LDL
cholesterol levels have tended to decrease. This study focused on changes in
LDL and total cholesterol levels since the previous NHANES survey from
1988-1994. Blood lipid measurements were examined in 5 cross-sectional
surveys in the US population during the periods 1960-1962, 1971-1974,
1976-1980, 1988-1994, 1999-2002. Mean serum total cholesterol, LDL
cholesterol, high density lipoprotein (HDL) cholesterol and mean serum
triglyceride levels and the percentage of adults with a total serum choles-
terol 240 mg/dl were determined. There were from 6,000 in 1998 to
15,019 adults examined in the 5 district cross-sectional surveys.
Between 1988-1994 and 1999-2002 total cholesterol level of 20 years
or older adults decreased from 206mg/dl to 203mg/dl (P 0.009). LDL
cholesterol levels decreased from 129 mg/dl to 123 mg/dl (P  0.001).
Men who are 60 years of age had more significant decreases than
women 50 years of age. Overall, the percentage of adults with a total
cholesterol level 240 mg/dl decreased from 20% during the period of
1988-1984 to 17% during the period of 1999-2002 (P  0.001). Mean
HDL levels did not change and there was a nonsignificant increase in mean
serum triglycerides (P  0.06).
Comment: The data indicate continued and sustained progress in
reducing cholesterol levels in the US population. Now only 17% of the US
adult population has a total cholesterol level 240 mg/dl. Clearly there is still
room for improvement and further analyses targeting the ability to reduce
cholesterol levels in patients particularly at high risk for coronary disease and
other forms of vascular disease is required.
Secondary Prevention of Macro Vascular Events in Patients With Type
II Diabetes in the PROactive Study (PROspective Pioglitazone Clinical
Trial and Macro Vascular Events): A Randomised Controlled Trial
Dormandy JA, Charbonnel B, Eckland DJA, et al. Lancet 2005;366:1279-89.
Conclusion: In patients with Type II diabetes felt to be at high risk for
macro vascular events, Pioglitazone reduces the combination of all cause
mortality, non fatal myocardial infarction, and stroke.
Summary: This study sought to evaluate the effects of an antagonist of
peroxisome proliferator-activated receptor gamma for its ability to reduce
macro vascular complications in patients with Type II diabetes. This was a
prospective, randomized control trial involving 5,238 patients with Type II
diabetes and who had evidence of macro vascular disease. Patients were
recruited from both hospitals and primary care practices. Patients were
divided into two groups with one group treated with a titrated dose of
pioglitazone from 15 mgs to 45 mgs (n  2,605) with the second group
being a placebo control (n 2,603) study.Medications in both groups were
taken in addition to glucose lowering drugs and other indicated medica-
tions. The primary end point in the study was a composite of all cause
mortality, non fatal myocardial infarction, stroke, acute coronary syndrome,
and endovascular or surgical intervention in the coronary or leg arteries, or
amputation above the ankle. An intention to treat analysis was utilized.
There were only two patients lost to followup in this study. Average
observation time was 34.5 months. In the pioglitazone group, 514 patients
had at least one event in the primary composite end point versus 572 patients
in the placebo group (hazard ratio 0.9, 95% CI, 0.8-1.02, P 0.095). With
regard to the combination of all cause morality, non fatal myocardial
infarction, and stroke, 301 patients in the Pioglitazone group and 358
patients in the placebo group achieved this end point (hazard ratio 0.84, 95%
CI, 0.72-0.98, P  0.027). There was no change in the safety profile of
Pioglitazone noted. During the course of the study, 6% of the patients in the
Pioglitazone group and 4% in the placebo group were admitted to the
hospital with heart failure. There was no difference in mortality rates from
heart failure between the two groups.Comment: Pioglitazone reduces levels of inflammatory markers such
as C-reactive protein. These effects are independent of its affect on glycemic
639
